Actualités Harbor ETF Trust Multi-Asset Explorer - MAPP | Actions New York Stock Exchange

Outils de qualité professionnelle, pour des investisseurs individuels.

MAP Pharmaceuticals Announces Initiation of LEVADEX(TM) Pharmacokinetics Trial

--Trial to be used in support of NDA submission-- MOUNTAIN VIEW, Calif., Feb. 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc...

MAP Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Jan. 6 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that the company will present at...

MAP Pharmaceuticals Secures $60 Million Committed Equity Financing Facility

MOUNTAIN VIEW, Calif., Nov. 12 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that it has secured a committed...

MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

MOUNTAIN VIEW, Calif., Nov. 11 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that the company will present...

MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients

MOUNTAIN VIEW, Calif., Oct. 29 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that it has completed a planned...

MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of

-- Analysis Shows Potential of LEVADEX to Treat a Broad Spectrum of Migraine -- -- Company to Host Webcast on Monday, September 14th at 7:15 a.m...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Harbor ETF Trust Multi-Asset Explorer (MAPP)

Outils de qualité professionnelle, pour des investisseurs individuels.

MAPP Actualités

MAP Pharmaceuticals Announces Initiation of LEVADEX(TM) Pharmacokinetics Trial

MAP Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

MAP Pharmaceuticals Secures $60 Million Committed Equity Financing Facility

MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients

MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of

MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences

MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration

MAP Pharmaceuticals Announces Pricing of Its Initial Public Offering

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Harbor ETF Trust Multi-Asset Explorer (MAPP) Actualités

Harbor ETF Trust Multi-Asset Explorer (MAPP)

Outils de qualité professionnelle, pour des investisseurs individuels.

MAPP Actualités

MAP Pharmaceuticals Announces Initiation of LEVADEX(TM) Pharmacokinetics Trial

MAP Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

MAP Pharmaceuticals Secures $60 Million Committed Equity Financing Facility

MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients

MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of

MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences

MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration

MAP Pharmaceuticals Announces Pricing of Its Initial Public Offering

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités